Table 2.
Characteristics and clinical outcome of EGFR‐mutated patients
| Patient | EGFR mutation detected | First‐line EGFR TKI | Clinical outcomea | PFS (months) | OS (months) | ECOG (prior to treatment) | ECOG (posttreatment) | Follow‐up (months) | Subsequent treatment |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EGFR 21 L858R | Gefitinib | PR (30.3%) | 7.00 | 7.00 | 4 | 1 | 7.00 | Gefitinib |
| 2 | EGFR 19 del | Gefitinib | PR (31.6%) | 10.00 | 12.00 | 3 | 2 | 12.00 | Chemotherapy (pemetrexed) + gefitinib |
| 3 | EGFR 19 del | Gefitinib | PR (50%) | 8.00 | 12.00 | 3 | 1 | 12.00 | Chemotherapy (pemetrexed) + gefitinib |
| 4 | EGFR 21 L858R | Gefitinib | PR (41.9%) | 11.00 | 12.00 | 3 | 0 | 12.00 | Chemotherapy (pemetrexed) + gefitinib |
| 5 | EGFR 19 del | Icotinib | PR (30.7%) | 6.00 | 8.00 | 3 | 1 | 8.00 | Chemotherapy (pemetrexed) + icotinib |
| 6 | EGFR 21 L858R | Icotinib | PR (34.6%) | 8.00 | 9.00 | 3 | 1 | 9.00 | Erlotinib due to brain metastases |
| 7 | EGFR 21 L858R | Gefitinib | PR (47.3%) | 10.00 | 16.00 | 3 | 0 | 16.00 | Chemotherapy (pemetrexed/carboplatin) + gefitinib |
| 8 | EGFR 21 L858R | Icotinib | PR (43.3%) | 10.00 | 10.00 | 3 | 1 | 10.00 | Gefitinib |
| 9 | EGFR 21 L858R | Gefitinib | PR (30%) | 14.00 | 20.00 | 4 | 1 | 20.00 | Bone radiotherapy + gefitinib |
| 10 | EGFR 19 del | Gefitinib | PR (32%) | 12.00 | 12.00 | 3 | 0 | 12.00 | Gefitinib |
| 11 | EGFR 19 del | Gefitinib | PR (31%) | 8.00 | 8.00 | 3 | 0 | 8.00 | Gefitinib |
| 12 | EGFR 21 L858R | Gefitinib | SD (5%) | 7.00 | 12.00 | 3 | 1 | 12.00 | Gefitinib |
| 13 | EGFR 19del | Erlotinib | PR (69.7%) | 6.00 | 17.00 | 3 | 1 | 17.00 | Osimertinib |
| 14 |
EGFR p.T790M EGFR p.G719A EGFR p.L861Q EGFR p747_752del |
Erlotinib | PR (33%) | 12.00 | 17.00 | 4 | 1 | 17.00 | Chemotherapy + erlotinib |
| 15 | EGFR 21 L858R | Icotinib | SD (10%) | 7.00 | 11.00 | 3 | 1 | 11.00 | Osimertinib |
| 16 | EGFR 21 L858R | Gefitinib | PR (31.5%) | 14.00 | 14.00 | 4 | 1 | 14.00 | Gefitinib |
| 17 | EGFR 19del | Gefitinib | PR (35%) | 7.00 | 7.00 | 4 | 1 | 7.00 | Gefitinib |
| 18 | EGFR 19del | Gefitinib | PR (31%) | 6.00 | 6.00 | 3 | 1 | 6.00 | Gefitinib |
| 19 | EGFR 21 L858R | Gefitinib | PR (39%) | 6.00 | 6.00 | 3 | 1 | 6.00 | Gefitinib |
| 20 | EGFR 19del | Gefitinib | PR (55.8%) | 10.00 | 10.00 | 3 | 1 | 10.00 | Gefitinib |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression‐free survival.
a
Maximum reduction from baseline (%).